Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241277695. doi: 10.1177/15330338241277695.
: To examine the effects of peripheral blood eosinophil (EOS) count and its dynamic alterations on the treatment efficacy and prognosis of patients with advanced hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) receiving camrelizumab combined with lenvatinib (C + L) therapy. : A retrospective analysis was performed on 200 patients with advanced HBV-HCC who were admitted to two centers from January 2018 to August 2023 and treated with C + L. EOS, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were determined before C + L treatment (EOS0, NLR0, and PLR0) and after three cycles of treatment (EOS3, NLR3, and PLR3). The area under the curve was calculated using the receiver operating characteristic (ROC) curve. NLR and PLR served as references to analyze the effect of differences in EOS in predicting the survival efficacy of patients with HBV-HCC treated using C + L. The independent risk factors affecting progression-free survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate Cox proportional risk models. : The ROC curve revealed that the predictive value of EOS3 was better than those of NLR3 and PLR3 for the long-term treatment efficacy of patients with intermediate and advanced HBV-HCC receiving C + L. Statistically significant differences were observed between groups with different levels of EOS0 and EOS3 and the evaluation of treatment efficacy after 3 weeks (< 0.05). The median PFS of the high-EOS0 group was higher than that of the low-EOS0 group (= 0.027); median PFS of the high EOS3 group was higher than that of the low EOS3 group (= 0.018); median OS of the high EOS0 group was higher than that of the low EOS0 group (= 0.032); median OS of the high EOS3 group was higher than that of the low EOS3 group (< 0.0001). Multifactorial Cox analysis revealed that EOS3 was an independent predictor of PFS and that EOS0 was an independent predictor of OS (0.05). : EOS may be an ideal indicator for predicting the treatment efficacy and prognosis of patients with advanced HBV-HCC receiving C + L.
目的：探讨外周血嗜酸性粒细胞（EOS）计数及其动态变化对接受卡瑞利珠单抗联合仑伐替尼（C+L）治疗的晚期乙型肝炎病毒相关性肝细胞癌（HBV-HCC）患者治疗效果和预后的影响。
方法：回顾性分析 2018 年 1 月至 2023 年 8 月在两个中心接受 C+L 治疗的 200 例晚期 HBV-HCC 患者的临床资料。在 C+L 治疗前（EOS0、NLR0 和 PLR0）和治疗 3 个周期后（EOS3、NLR3 和 PLR3）检测 EOS、中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）。采用受试者工作特征（ROC）曲线计算曲线下面积。NLR 和 PLR 作为参考，分析 EOS 差异预测 C+L 治疗的 HBV-HCC 患者生存疗效的效果。采用单因素和多因素 Cox 比例风险模型分析影响无进展生存期（PFS）和总生存期（OS）的独立危险因素。
结果：ROC 曲线显示，EOS3 对接受 C+L 治疗的中晚期 HBV-HCC 患者的长期治疗效果的预测价值优于 NLR3 和 PLR3。EOS0 和 EOS3 水平不同的组之间以及治疗 3 周后的疗效评估之间存在统计学差异（<0.05）。高 EOS0 组的中位 PFS 高于低 EOS0 组（=0.027）；高 EOS3 组的中位 PFS 高于低 EOS3 组（=0.018）；高 EOS0 组的中位 OS 高于低 EOS0 组（=0.032）；高 EOS3 组的中位 OS 高于低 EOS3 组（<0.0001）。多因素 Cox 分析显示，EOS3 是 PFS 的独立预测因子，EOS0 是 OS 的独立预测因子（0.05）。
结论：EOS 可能是预测接受 C+L 治疗的晚期 HBV-HCC 患者治疗效果和预后的理想指标。
Hum Vaccin Immunother. 2023-12-31
Zotero 插件
